Baird raised the firm’s price target on Cencora (COR) to $292 from $287 and keeps an Outperform rating on the shares. The firm said they delivered another solid report, guided favorably, and announced a very intriguing MSO deal in a new field for distributors; retina care specialists.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.